PEIJIA-B (09996) shares rose more than 5% in trading, currently up 4.75% to HK$5.29, with a turnover of HK$2.8668 million.

The company recently disclosed that its first-half revenue is expected to be approximately RMB 415 million to RMB 435 million, representing a year-on-year increase of about 17.4% to 23.1%. This growth is primarily driven by the continued expansion of its transcatheter valve therapy business, supported by the successful commercialization of new indication products, and sustained growth in its neurointerventional business, fueled by the penetration of self-developed products and strategic collaborations.

During the reporting period, total TAVR implants reached approximately 2,830 units, a significant increase of about 36.5% compared to the same period last year, with hospital coverage expanding to over 850 hospitals in Greater China. Additionally, the TaurusTrio®, specifically designed for aortic regurgitation (AR), has been commercialized and has seen over 660 implants in mainland China, demonstrating strong clinical acceptance and commercial potential.